Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2017 Financial Results on Thursday, May 4, 2017
April 18 2017 - 8:35AM
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical
company focused on bringing innovative medicines to people with
renal disease, today announced that it will host a conference call
and webcast on Thursday, May 4, 2017 at 8:00 a.m. ET to discuss its
first quarter 2017 financial results and provide corporate updates.
To participate in the conference call, please dial
1-888-396-2320 (U.S.), 1-774-264-7560 (international) and refer to
conference ID: 8810002. The call will be webcast live with slides
and accessible through the Investors section of the company’s
website at www.keryx.com for a period of 15 days after the
call.
Keryx Biopharmaceuticals will announce its financial results for
this period in a press release to be issued prior to the call.
About Keryx Biopharmaceuticals, Inc. Keryx
Biopharmaceuticals, Inc., with headquarters in Boston,
Massachusetts is a commercial stage company focused on bringing
innovative medicines to people with renal disease. Keryx developed
and commercializes Auryxia® (ferric citrate) in the U.S. Ferric
citrate is marketed as Riona® by Keryx’s Japanese
partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In
September 2015, the European Commission granted European market
authorization for Fexeric® (ferric citrate coordination
complex). Keryx has programs underway to leverage its
development and commercial infrastructure, including potentially
expanding the indication of Auryxia and in-licensing medicines
for renal disease. For more information about Keryx, please
visit www.keryx.com.
Keryx Biopharmaceuticals Contact:
Lora Pike
Senior Director, Investor Relations & Corporate Communications
T: 617.466.3511
lora.pike@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2024 to May 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From May 2023 to May 2024